Related Experiment Video
Updated: Jan 21, 2026

Experimental Glaucoma Induced by Ocular Injection of Magnetic Microspheres
Published on: February 2, 2015
[Selective α2 agonists in the treatment of glaucoma: neuroprotective properties and impact on ocular blood flow]
1Ophthalmological Center of the Federal Medical-Biological Agency of the Russian Federation, State Research Center Burnasyan Federal Medical Biophysical Center of the Federal Medical-Biological Agency, Academy of postgraduate education under FSBU FSCC of FMBA of Russia, Department of Ophthalmology, 15 Gamalei St., Moscow, Russian Federation, 123098.
Abstract:
Glaucoma is the main cause of irreversible blindness in the world. The selective α2 adrenergic receptor agonist brimonidine holds an important place among the hypotensive eye drops. The second part of this review focuses on some important effects of brimonidine that characterizes it as a medication with direct neuroprotective multifactorial action, discusses its influence on ocular blood flow and highlights its capability to maintain normal autoregulation of ocular blood flow.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Blood Flow
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Autoregulation of Blood Flow
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation....
Glaucoma: Overview

